

# Human Chandipura (CHPV) IgM ELISA

**Domain:** Diagnostic Assay/Kit

**About Technology:** CHPV causes high fatality in children; early detection via IgM antibodies is vital. This is the first indigenous Human CHPV IgM ELISA kit. The kit supports surveillance to identify high-risk regions

**Intended Use:** Qualitative detection of IgM antibodies in serum or CSF from patients with symptoms suggestive of CHPV encephalitis. Suitable for laboratory diagnosis of CHPV at sentinel hospitals and primary health centers.



**Advantages:**

- First indigenous Human CHPV IgM ELISA kit
- Sensitive, rapid and user friendly
- Safe for BSL-2 labs
- Cost effective

**Development Status:** Third party validation complete

**Technology Transfer Status:** Transferred to companies on Non-Exclusive basis (Some licensees have already received Manufacturing License from CDSCO)

**Institute(s):** ICMR-National Institute of Virology (NIV)

**Inventor(s):** Dr. GN Sapkal, Dr. VP Bondre

For Licensing Opportunities contact: [patentmitra.hq@icmr.gov.in](mailto:patentmitra.hq@icmr.gov.in)